HIV Multiplex RT-PCR Primers for Strain-Independent Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV immunotherapies based on consensus antigens have limited efficacy due to sequence divergence between autologous and consensus antigens, and existing RT-PCR amplification methods face challenges in amplifying variant HIV strains without prior knowledge of target sequences, necessitating improved primers for strain-independent amplification of HIV nucleic acids.
Innovation Solution
Development of novel primers and methods for amplifying HIV Rev, Gag, and Nef nucleic acids using multiplex RT-PCR strategies with specific primer compositions that include Rev T7 promoter primers, Rev reverse primers, Gag reverse primers, and Nef forward and reverse primers, allowing for efficient amplification of multiple HIV quasispecies, including non-Clade B strains, and enhancing transcriptional and translational expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If consensus antigen-based immunotherapies are used, then standardization and ease of manufacture are improved, but efficacy is reduced due to sequence divergence between autologous and consensus antigens
Solution Approach 1:
The patent segments the HIV genome into specific genes (GAG, REV, NEF) and uses gene-specific primers to amplify only those regions. This segmentation allows for standardized amplification of conserved regions while maintaining the ability to adapt to patient-specific variants, thereby balancing standardization with efficacy.
Solution Approach 2:
The patent applies local quality by designing primers that target specific conserved regions within the HIV genome while allowing for patient-specific variations in other regions. The primers are engineered with degenerate bases to accommodate local sequence variations, ensuring both standardization of the approach and adaptation to local patient-specific sequences.
2Adaptability or versatility
If RT-PCR amplification is performed without prior knowledge of target sequences, then adaptability to variant HIV strains is improved, but amplification precision and reliability deteriorate
Solution Approach 1:
The patent creates universal primers that can amplify multiple HIV strains and variants simultaneously. The primers are designed to target conserved regions across different HIV clades, enabling a single primer set to function across diverse viral strains without requiring prior knowledge of the specific variant present in the patient sample.
Solution Approach 2:
The patent uses parameter changes by incorporating degenerate bases in the primer sequences to accommodate sequence variations. This allows the primers to bind effectively to a range of HIV variants while maintaining sufficient binding affinity for reliable amplification, thus preserving amplification precision across different strains.
3Adaptability or versatility
If multiple HIV quasispecies are amplified simultaneously, then broader immune response is improved, but primer design complexity and device complexity increase
Solution Approach 1:
The patent merges multiple amplification targets (GAG, REV, NEF genes) into a single multiplex RT-PCR reaction. By combining these targets in one reaction using a set of coordinated primers, the method achieves broad quasispecies coverage without requiring separate amplification reactions for each gene or variant, thus reducing overall procedural complexity.
Solution Approach 2:
The primer set is designed with universal functionality to simultaneously amplify multiple HIV genes and variants in a single reaction. This multi-functional primer design eliminates the need for multiple separate reactions, reducing the complexity of the overall amplification process while maintaining broad coverage of HIV quasispecies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new primer compositions improve the amplification and detection of HIV nucleic acids, leading to enhanced immune responses and potentially broader applicability by targeting autologous viral antigens, with improved yield and safety profiles compared to previous methods.
Implementation Method 1
Primers and probes for the amplification and detection of HIV GAG, REV and NEF polynucleotides
Implementation Method 2
amplification of multiple HIV quasispecies
Data Source
AI summary
The invention relates to improved methods and compositions for the nucleic acid amplification of one or multiple variants (strains) of Human Immunodeficiency Virus (HIV) present in a sample, and preferably in a sample from a pathogen infected individual. In particular, novel primers, methods and kits for the amplification of one or more species of HIV Rev, Gag and Nef nucleic acids are provided. The amplified HIV nucleic acid can be used to identify and/or quantitate HIV variants present in a sample. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can also be used directly as vaccines or to transfect/load antigen presenting cells. The loaded antigen presenting cells can be used as a vaccine for the treatment or prevention of HIV infection.